FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lisa Hammond

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Jordi Rodon; Mitchell Garrison; Lisa A Hammond; Johann S de Bono; Lon Smith; Leonardo Forero; Desirée Hao; Chris H Takimoto; John M Lambert; Lini Pandite; Maria Howard; Hongsheng Xie; Anthony W Tolcher
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Monica Mita; Eric K Rowinsky; Leonardo Forero; S Gail Eckhart; Elzbieta Izbicka; Geoffrey R Weiss; Muralidhar Beeram; Catalin Mita; Johann S de Bono; Anthony W Tolcher; Lisa A Hammond; Paul Simmons; Kristin Berg; Chris H Takimoto; Amita Patnaik
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Eric K Rowinsky; Muralidhar Beeram; Lisa A Hammond; Garry Schwartz; Johann S de Bono; Bahram Forouzesh; Quincy Chu; Jane E Latz; Shengyan Hong; William John; Binh Nguyen
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lisa Hammond (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Jordi Rodon; Mitchell Garrison; Lisa A Hammond; Johann S de Bono; Lon Smith; Leonardo Forero; Desirée Hao; Chris H Takimoto; John M Lambert; Lini Pandite; Maria Howard; Hongsheng Xie; Anthony W Tolcher
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Cancer chemotherapy and pharmacology 2008;62(5):911-9.
2007: Monica Mita; Eric K Rowinsky; Leonardo Forero; S Gail Eckhart; Elzbieta Izbicka; Geoffrey R Weiss; Muralidhar Beeram; Catalin Mita; Johann S de Bono; Anthony W Tolcher; Lisa A Hammond; Paul Simmons; Kristin Berg; Chris H Takimoto; Amita Patnaik
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology 2007;59(2):165-74.
2007: Eric K Rowinsky; Muralidhar Beeram; Lisa A Hammond; Garry Schwartz; Johann S de Bono; Bahram Forouzesh; Quincy Chu; Jane E Latz; Shengyan Hong; William John; Binh Nguyen
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):532-9.
2006: Amita Patnaik; Debra Wood; Anthony W Tolcher; Marta Hamilton; Jeffrey I Kreisberg; Lisa A Hammond; Garry Schwartz; Muralidhar Beeram; Manuel Hidalgo; Monica Mita; Julie Wolf; Paul Nadler; Eric K Rowinsky
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7406-13.
2006: Catalin Mita; Lisa A Hammond; Peter L Bonate; Geoffrey Weiss; Heather McCreery; Samira Syed; Mitchell Garrison; Quincy S C Chu; Johann S DeBono; Christopher B Jones; Steven D Weitman; Eric K Rowinsky
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5207-15.
2006: Larry J Schaaf; Lisa A Hammond; Stuart J Tipping; Richard M Goldberg; Rakesh Goel; John Kuhn; Langdon L Miller; Linda D Compton; Laura A Cisar; Gary L Elfring; Gabriela Gruia; J Patrick McGovren; Nicoletta Pirotta; Donghua Yin; Amarnath Sharma; Barbara A Duncan; Mace L Rothenberg
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3782-91.
2006: Anthony W Tolcher; Desiree Hao; Johann S de Bono; Alex Miller; Amita Patnaik; Lisa A Hammond; Leslie Ann Smetzer; Jill van Wart Hood; James Merritt; Eric K Rowinsky; Chris H Takimoto; Daniel Von Hoff; S Gail Eckhardt
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2006: Catalin Mita; Christopher J Sweeney; Sharyn D Baker; Andrew Goetz; Lisa A Hammond; Amita Patnaik; Anthony W Tolcher; Miguel A Villalona-Calero; Alan B Sandler; Tuhin Chaudhuri; Kathleen Molpus; Jane E Latz; Lorinda Simms; Ajai K Chaudhary; Robert D Johnson; Eric K Rowinsky; Chris H Takimoto
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):552-62.
2006: Monica Mita; Leonel Ochoa; Eric K Rowinsky; John Kuhn; Garry Schwartz; Lisa A Hammond; Amita Patnaik; I-Tien Yeh; Elzbieta Izbicka; Kristin Berg; Anthony W Tolcher
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):313-21.
2005: Alejandro D Ricart; Lisa A Hammond; John Kuhn; Chris H Takimoto; Andrew Goetz; Bahram Forouzesh; Leonardo Forero; Jose L Ochoa-Bayona; Kristin Berg; Anthony W Tolcher; Eric K Rowinsky
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8728-36.
2005: Casey Cunningham; Leonard J Appleman; Miora Kirvan-Visovatti; David P Ryan; Eileen Regan; Svetislava Vukelja; Peter L Bonate; Francis Ruvuna; Robert J Fram; Antti Jekunen; Steven D Weitman; Lisa A Hammond; Joseph P Eder
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7825-33.
2005: Scot W Ebbinghaus; Eric Rubin; Evan M Hersh; Lee D Cranmer; Peter L Bonate; Robert J Fram; Antti Jekunen; Steven D Weitman; Lisa A Hammond
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7807-16.
2004: Johann S de Bono; S Y Rha; J Stephenson; Birgit C Schultes; Pamela Monroe; G S Eckhardt; Lisa A Hammond; T L Whiteside; Christopher F Nicodemus; J M Cermak; Eric K Rowinsky; Anthony W Tolcher
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1825-33.
2004: Johann S de Bono; Anthony W Tolcher; Andre Forero; Gertrude F A Vanhove; Chris H Takimoto; Robert J Bauer; Lisa A Hammond; Amita Patnaik; Mark L White; Sui Shen; Muhammad B Khazaeli; Eric K Rowinsky; Albert F LoBuglio
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7555-65.
2004: Emiliano Calvo; Anthony W Tolcher; Lisa A Hammond; Amita Patnaik; Johann S de Bono; Irene A Eiseman; Stephen C Olson; Peter F Lenehan; Heather McCreery; Patricia M LoRusso; Eric K Rowinsky
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7112-20.
2004: Samira Syed; Chris H Takimoto; Manuel Hidalgo; Jinee Rizzo; John Kuhn; Lisa A Hammond; Garry Schwartz; Anthony W Tolcher; Amita Patnaik; S Gail Eckhardt; Eric K Rowinsky
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6512-21.
2004: Anthony W Tolcher; John Kuhn; Garry Schwartz; Amita Patnaik; Lisa A Hammond; Ian M Thompson; Howard Fingert; David Bushnell; Shazli Malik; Jeffrey I Kreisberg; Elzbieta Izbicka; Leslie Ann Smetzer; Eric K Rowinsky
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5048-57.
2004: Quincy S C Chu; Lisa A Hammond; Garry Schwartz; Leonel Ochoa; Sun-Young Rha; Louis Denis; Kathleen Molpus; Brian Roedig; Stephen P Letrent; Bharat Damle; Arthur P DeCillis; Eric K Rowinsky
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4913-21.
2004: Robert F Melendez; Joseph Harrison; Eric K Rowinsky; Lisa A Hammond; Thomas D Fitzsimmons
Acute retinal toxicity from the novel anti-tumor agent, Irofulven.
Documenta ophthalmologica. Advances in ophthalmology 2004;108(3):249-51.
2004: Lisa A Hammond; John R Eckardt; John Kuhn; Stanton L Gerson; Tom Johnson; Lon Smith; Ronald L Drengler; Elizabeth Campbell; Geoffrey R Weiss; Daniel Von Hoff; Eric K Rowinsky
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
2003: Bahram Forouzesh; Chris H Takimoto; Andrew Goetz; Sami Diab; Lisa A Hammond; Leslie Ann Smetzer; Garry Schwartz; Robert Gazak; John T Callaghan; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5540-9.
2003: Amita Patnaik; S Gail Eckhardt; Elzbieta Izbicka; Anthony A Tolcher; Lisa A Hammond; Chris H Takimoto; Garry Schwartz; Heather McCreery; Andrew Goetz; Masataka Mori; Kazutoyo Terada; Lou Gentner; Mary-Ellen Rybak; Henry Richards; Steven Zhang; Eric K Rowinsky
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4761-71.
2003: Roy S Herbst; Lisa A Hammond; David P Carbone; Hai T Tran; Kenneth J Holroyd; Avinash Desai; Jon I Williams; B Nebiyou Bekele; Howard Hait; Victoria Allgood; Stephen Solomon; Joan H Schiller
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4108-15.
2003: Lisa A Hammond
Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.
Clinical lung cancer 2003;5 Suppl 1():S18-21.
2003: Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles Thomas; John Kuhn
Positron emission tomography (PET): expanding the horizons of oncology drug development.
Investigational new drugs 2003;21(3):309-40.
2003: Mitchell Garrison; Lisa A Hammond; Charles E Geyer; Garry Schwartz; Anthony W Tolcher; Leslie Ann Smetzer; Jose A Figueroa; Murray Ducharme; John Coyle; Chris H Takimoto; Robert L De Jager; Eric K Rowinsky
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2527-37.
2003: Shazli N Malik; Lillian L Siu; Eric K Rowinsky; Linda A de Graffenried; Lisa A Hammond; Jinee Rizzo; Sarah S Bacus; Michael G Brattain; Jeffrey I Kreisberg; Manuel Hidalgo
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2478-86.
2003: Desirée Hao; Lisa A Hammond; S Gail Eckhardt; Amita Patnaik; Chris H Takimoto; Garry H Schwartz; Andrew D Goetz; Anthony W Tolcher; Heather McCreery; Khalid Mamun; Jon I Williams; Kenneth J Holroyd; Eric K Rowinsky
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2465-71.
2003: Garry H Schwartz; Amita Patnaik; Lisa A Hammond; Jinee Rizzo; K Berg; Daniel Von Hoff; Eric K Rowinsky
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):775-82.
2003: Anthony W Tolcher; S L Gerson; Louis Denis; Charles E Geyer; Lisa A Hammond; Amita Patnaik; A D Goetz; Garry Schwartz; T Edwards; Larisa Reyderman; Paul Statkevich; David L Cutler; Eric K Rowinsky
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
British journal of cancer 2003;88(7):1004-11.
2003: Anthony W Tolcher; Leonel Ochoa; Lisa A Hammond; Amita Patnaik; Tam Edwards; Chris H Takimoto; Lon Smith; Johann S de Bono; Garry Schwartz; Theresa Mays; Zdenka L Jonak; Randall Johnson; Mark DeWitte; Helen Martino; Charlene Audette; Kate Maes; Ravi V J Chari; John M Lambert; Eric K Rowinsky
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):211-22.
2003: Eric K Rowinsky; Jinee Rizzo; Leonel Ochoa; Chris H Takimoto; Bahram Forouzesh; Garry Schwartz; Lisa A Hammond; Amita Patnaik; Joseph Kwiatek; Andrew Goetz; Louis Denis; Jeffrey McGuire; Anthony W Tolcher
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):148-57.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Amita Patnaik; Eric K Rowinsky; Miguel A Villalona; Lisa A Hammond; Carolyn D Britten; Lillian L Siu; Andrew Goetz; Sally A Felton; Susan Burton; Frank H Valone; S Gail Eckhardt
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2142-8.
2002: Johann S de Bono; Joseph Stephenson; Sharyn D Baker; Manuel Hidalgo; Amita Patnaik; Lisa A Hammond; Geoffrey Weiss; Andrew Goetz; Lillian Siu; Cecilia Simmons; Jacques Jolivet; Eric K Rowinsky
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):96-109.
2001: Mace L Rothenberg; John Kuhn; L J Schaaf; Gladys I Rodriguez; S Gail Eckhardt; Miguel A Villalona-Calero; David A Rinaldi; Lisa A Hammond; S Hodges; A Sharma; Gary L Elfring; R G Petit; Paula K Locker; Langdon L Miller; Daniel Von Hoff
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1631-41.
2001: Manuel Hidalgo; Lillian L Siu; J Nemunaitis; Jinee Rizzo; Lisa A Hammond; Chris H Takimoto; S Gail Eckhardt; Anthony W Tolcher; Carolyn D Britten; Louis Denis; K Ferrante; Daniel Von Hoff; S Silberman; Eric K Rowinsky
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Lisa A Hammond; K Davidson; R Lawrence; Jim B Camden; Daniel Von Hoff; Steven D Weitman; Elzbieta Izbicka
Exploring the mechanisms of action of FB642 at the cellular level.
Journal of cancer research and clinical oncology 2001;127(5):301-13.
2001: Manuel Hidalgo; Cheryl Aylesworth; Lisa A Hammond; Carolyn D Britten; Geoffrey Weiss; Joseph Stephenson; Garry Schwartz; Amita Patnaik; Lon Smith; Kathleen Molpus; Sally A Felton; E Gupta; K J Ferrante; A Tortora; Daryl Sonnichsen; J Skillings; Eric K Rowinsky
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2493-503.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Amita Patnaik; Eric K Rowinsky; B K Tammara; Manuel Hidalgo; Ronald L Drengler; A M Garner; Lillian L Siu; Lisa A Hammond; Sally A Felton; S Mallikaarjun; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Lisa A Hammond; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Eric K Rowinsky; T R Johnson; Charles E Geyer; Lisa A Hammond; S Gail Eckhardt; Ronald L Drengler; Leslie Ann Smetzer; John Coyle; Jinee Rizzo; Garry Schwartz; Anthony W Tolcher; Daniel Von Hoff; Robert L De Jager
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: Eric K Rowinsky; R Humphrey; Lisa A Hammond; Cheryl Aylesworth; Leslie Ann Smetzer; Manuel Hidalgo; M Morrow; Lon Smith; A Garner; J M Sorensen; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Manuel Hidalgo; Miguel A Villalona-Calero; S Gail Eckhardt; Ronald L Drengler; G Rodriguez; Lisa A Hammond; Sami Diab; Geoffrey Weiss; A M Garner; Elizabeth Campbell; K Davidson; A Louie; J D O'Neil; R von Borstel; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; S S Agarwala; John R Eckardt; RE Barrington; Sami Diab; Lisa A Hammond; T Johnson; Miguel A Villalona-Calero; U Fraass; Paul Statkevich; Daniel Von Hoff; S Gail Eckhardt
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: Ronald L Drengler; John Kuhn; Larry J Schaaf; Gladys I Rodriguez; Miguel A Villalona-Calero; Lisa A Hammond; J A Stephenson; S Hodges; Maura Kraynak; B A Staton; Gary L Elfring; Paula K Locker; Langdon L Miller; Daniel Von Hoff; Mace L Rothenberg
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):685-96.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.